Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (April 2021)
14 slides from Bio-gene Technology's investor presentation, Apr 15, 2021
Slide 1: Bio-Gene Technology Limited: Enabling the Next Generation of Novel Insecticides
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED 15 APRIL 2021 Monsoon Twilight Investor Briefing Presentation PRESENTED BY Richard Jagger Chief Executive Officer & Managing Director
Slide 2: Addressing Significant Global Challenges
CORPORATE PRESENTATION ADDRESSING SIGNIFICANT “At present, there are more than 16,000 documented cases of insecticide resistance involving more than 600 insect and mite species that have developed resistance to at least one insecticide. GLOBAL CHALLENGES Most of the primary pest species impacting th
Slide 3: Our Technology Addresses These Challenges and Targets Growing Global Markets
CORPORATE PRESENTATION OUR TECHNOLOGY ADDRESSES THESE CHALLENGES AND TARGETS GROWING GLOBAL MARKETS Bio-Gene’s insecticide platform has potential Crop Protection Food, Fibre & Grain application in large, global market segments Storage 52% estimated to represent a total addressable market Includes gr
Slide 4: The Value of Insecticides
CORPORATE PRESENTATION Food Security & Public Health Growing Population Current global population is 7.7 billion, growing at 70 million p.a. It is THE VALUE OF Less Arable Land anticipated that global population will reach nearly 10 billion by 20501. Increased population puts pressure on available l
Slide 5: Our Technology Platform
CORPORATE PRESENTATION OUR TECHNOLOGY PLATFORM We are developing two products that allow entry into five key market segments QcideTM FlavocideTM Natural Compound Nature Identical Compound Both of our products An extract of a specific cultivar of BGT has developed a proprietary have potential applica
Slide 6: Our Proprietary Chemistry Represents a Step-Change for Resistant Pest Control
CORPORATE PRESENTATION OUR PROPRIETARY CHEMISTRY REPRESENTS A STEP-CHANGE FOR RESISTANT PEST CONTROL Naturally Derived Chemistry Safe Chemistry Efficacy Novel Mode of Action QcideTM is a natural compound Excellent safety profile based on Testing to date confirms potential Operates via a novel and Fl
Slide 7: Creating Multiple Product Development Opportunities
CORPORATE PRESENTATION CREATING MULTIPLE Bio-Gene can generate income and Multiple Material Transfer Agreements PRODUCT DEVELOPMENT incremental company value as provide the opportunity for agreements to agreements are signed with commercial be developed across various market partners segments with n
Slide 8: Stored Grain Pest Evaluation Program
CORPORATE PRESENTATION STORED GRAIN Stage 1 identified optimum Testing also identified minimum PEST EVALUATION product combination for control of the major pest, the Lesser application rates to be effective against resistant pests PROGRAM grain borer AUSTRALIA Stage 2 testing demonstrated Stage 3 (f
Slide 9: Mosquito Evaluation Program
CORPORATE PRESENTATION MOSQUITO Agreement entered into in April Testing commenced in EVALUATION 2020 September 2020 to assess various solvents as base carriers PROGRAM THE AMERICAS Evaluating Flavocide and Qcide Expect to then test lead for use in public health formulations on target species in mosq
Slide 10: A Clear Road Map for Adding Value: Short Term
CORPORATE PRESENTATION A CLEAR ROAD MAP CY21 Q4 FOR ADDING VALUE CY21 Q3 SHORT TERM ▪ Confirmation of yield improvements CY21 Q2 via extraction process at Qcide ▪ Flavocide 5-batch harvest manufacturing ▪ BASF / GRDC phase CY21 Q1 analysis (for 3 results registration) ▪ Flavocide ▪ Qcide Tree planti
Slide 11: A Clear Road Map for Generating Value 2024-2026
CORPORATE PRESENTATION A CLEAR ROAD MAP FOR GENERATING VALUE 2024-2026 CRITICAL VALUE ADDING & DE-RISKING STEPS 2022-2024 2021-2022 • First regulatory approval and 2020-2021 • Additional commercial sales application testing - • Additional 2018-2020 • Manufacturing scale- internal and with registrati
Slide 12: Funding Position
CORPORATE PRESENTATION FUNDING POSITION Sources of future funding: Shares on issue 153,633,357 Market capitalisation $23.0 million1 Development Government Philanthropic As at December 31, 2020, and commercial grants organisations Cash on hand partnerships focused on public health solutions A$5.0 mil
Slide 13: Key Investment Highlights
CORPORATE PRESENTATION KEY INVESTMENT HIGHLIGHTS Proprietary insecticide Expanding efficacy, Large addressable technology toxicity and markets Naturally derived manufacturing data where insecticide chemistry, with novel mode to support international resistance is a growing of action regulatory submi
Slide 14: Contact
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED CONTACT RICHARD JAGGER CHIEF EXECUTIVE OFFICER richardj@bio-gene.com.au
Bio-Gene Technology — Investor Presentation (April 2021) on 6ix